Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GH Research ( (GHRS) ) has shared an announcement.
On January 13, 2026, GH Research PLC announced that it would present clinical results from its Phase 2b GH001-TRD-201 trial in treatment-resistant depression at the Promising Targets Oral Session of the 64th American College of Neuropsychopharmacology annual meeting, held January 12–15, 2026, in Nassau, Bahamas. The ACNP presentation, delivered by Professor Michael E. Thase, highlights data indicating that GH001 improved illness severity, anxiety symptoms and quality of life over up to six months of follow-up, underscoring the candidate’s potential to address the substantial unmet need in treatment-resistant depression and reinforcing GH Research’s positioning among emerging developers of fast-acting psychedelic medicines.
The most recent analyst rating on (GHRS) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held back primarily by weak operating fundamentals (no revenue, widening losses, and significant cash burn), partially offset by a strong, low-debt balance sheet. Technicals are moderately supportive with price above key moving averages, while valuation remains constrained due to negative earnings and no dividend data.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is an Ireland-based biopharmaceutical company focused on developing novel psychedelic-based therapies for psychiatric disorders, with a particular emphasis on treatment-resistant depression. Its lead candidate, GH001, is a synthetic form of mebufotenin (5-MeO-DMT) administered via pulmonary inhalation and is being evaluated for its potential to offer rapid, durable relief of depressive symptoms and improvements in anxiety and quality of life in patients who do not respond to standard treatments.
Average Trading Volume: 439,677
Technical Sentiment Signal: Buy
Current Market Cap: $931.1M
See more insights into GHRS stock on TipRanks’ Stock Analysis page.